What is CML SUN?
CML SUN is a global patient and physician survey by Novartis that explored the unmet needs of people living with CML.
A total of 361 patients and 198 physicians (hematologists and/or oncologists) in 11 countries (Australia, Brazil, Canada, France, Germany, Italy, Japan, South Korea, Spain, the UK, and the US) participated from November 2022 to March 2023. The findings revealed that there needs to be more communication and shared decision-making between patients and treatment providers; patients need therapy options that are both effective and tolerable; and that discussions between doctors and patients should balance quality of life, effectiveness and tolerability of treatment.
For more detailed information about the survey, click here.
To see the full-size poster that was presented at the European Hematology Association Congress 2023, click on the image below.
